Consensus $173.67M. Sees FY25 operating expenses $284.5M-$286.5M. The company said, “Operating profitability anticipated in the second half of 2026, excluding stock-based compensation.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals files automatic mixed securities shelf
- Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M
- Needham ups Vaxcyte target, adds to Conviction List
- Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks
- Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James